28
Jan
2010
Posted in I - Series C, Q - 4Q09, R - INTERNATIONAL, X - Asthma, X - Inflammation, X - Respiratory, X - Rhinitis
Oxagen (United Kingdom) a clinical-stage biopharmaceutical company focused on asthma and allergic rhinitis based drug company focused on inflammation, closed a $25.M Series C financing. Participants include MPM Capital, SV Life Sciences, Advent Ventures, Bessemer Venture Partners, Omega Ventures, Abingworth, International Bio Trust, Red Abbey Venture Partners and Wellcome Trust.
Note: 2009 Year-in-Review Trend Analysis Coming [...]
21
Jan
2010
Posted in I - Series A, Q - 4Q09, R - NORTH WEST, X - Device (Diagnostic), XX - WA
Integrated Diagnostics (Seattle, WA) a development-stage diagnostics company focused on rapid biomarker validation and parallel organ-centric assays, closed a $30M Series A financing. Participants include Interwest Partners, The Wellcome Trust and Dievini Hopp Biotech Holding.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.
17
Jan
2010
Posted in I - Series B, Q - 4Q09, R - INTERNATIONAL, X - Antiinfective, X - MRSA
Nabriva Therapeutics (Austria) a clinical-stage based developer of antibiotics for treating multi-drug resistant pathogens, closed a $22M Series B financing. Participants include Nomura Phase 4 Ventures, HBM Partners, Wellcome Trust, GLS Ventures and Novartis Venture Fund.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.